Every Form 4 that Nuvectis Pharma, Inc. (NVCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVCT filings page.
Carson Michael J. reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma, Inc. granted Vice President, Finance Michael J. Carson 30,000 shares of restricted common stock on August 3, 2026. These shares will fully vest on August 3, 2027, subject to his continued service. Following this award, he directly holds 230,118 shares of common stock, including restricted shares.
Nuvectis Pharma, Inc. disclosed that Emerald Hill Ventures SARL SPF, which is beneficially owned by 10% owner Charles Mosseri Marlio, executed an open-market purchase of 50,000 shares of common stock at a weighted average price of $18.32 per share. After these transactions, Emerald Hill Ventures SARL SPF holds 3,186,576 shares indirectly, while Marlio also directly owns 109,321 shares of Nuvectis Pharma common stock.
Nuvectis Pharma Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share in an open-market purchase tied to a public offering announced on June 29, 2026, for a total of $250,000.
After this transaction, he directly owns 3,688,424 shares of Nuvectis Pharma common stock, including shares of restricted common stock.
Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma, Inc. director Kenneth Hoberman received a grant of 35,000 shares of restricted common stock. The award was granted at no cash cost per share and is a form of equity compensation rather than an open-market purchase.
The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Hoberman continues serving on the company’s Board of Directors. After this grant, he directly holds 168,140 shares of common stock, which includes restricted shares.
Oliviero James F III reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director James F. Oliviero III received a grant of 35,000 shares of restricted common stock. These shares were awarded at no cash cost to him and are part of his equity compensation.
The restricted stock will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the company’s Board of Directors. Following this grant, he holds a total of 122,828 shares of Nuvectis Pharma common stock, including restricted shares.
Sanchez Juan reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director Juan Sanchez received a grant of 35,000 shares of restricted common stock at no cost. The award will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the Board of Directors.
After this grant, Sanchez holds 113,380 common shares directly and 415 shares indirectly as custodian for his son. The filing also notes that his current holdings include 230 restricted shares that had been inadvertently omitted from his earlier Form 3.
Kaplan Matthew L. reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director Matthew L. Kaplan received a grant of 35,000 shares of restricted common stock. The award was made at no cash cost per share and is classified as a compensation-related grant rather than an open-market purchase.
The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Kaplan continues to serve on the Board of Directors on those dates. After this grant, he directly holds 159,760 shares of Nuvectis Pharma common stock, including restricted shares.
Nuvectis Pharma, Inc. reported that Chief Dev. & Ops. Officer Shay Shemesh received an award of 150,000 shares of restricted common stock on 01/06/2026 at a price of $0 per share.
The restricted shares will vest in equal annual installments over three years beginning on the first anniversary of the grant date, subject to his continued service. After this grant, Shemesh beneficially owns 1,793,068 shares of Nuvectis common stock, including restricted shares, held directly.
Nuvectis Pharma, Inc. reported an equity award to its Chairman and CEO, Ron Bentsur. On 01/06/2026, he was granted 150,000 shares of restricted common stock at a price of $0 per share. These restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues to serve with the company on each vesting date.
After this grant, Mr. Bentsur beneficially owns 3,675,924 shares of Nuvectis Pharma common stock, held directly, which includes previously granted restricted shares.
Nuvectis Pharma, Inc. reported an equity grant to a senior officer. Chief Science & Business Officer Enrique Poradosu received 150,000 shares of restricted common stock on January 6, 2026, at a stated price of $0 per share, reflecting a compensatory award rather than an open-market purchase.
The 150,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Poradosu’s continued service on each vesting date. Following this grant, he beneficially owned 1,806,319 shares of Nuvectis common stock, which includes restricted shares.
Nuvectis Pharma vice president receives new equity grant. Nuvectis Pharma, Inc. reported that its Vice President of Finance, Michael J. Carson, was awarded 61,200 shares of restricted common stock on January 6, 2026. The grant was priced at $0 per share, reflecting a stock award rather than an open-market purchase.
The 61,200 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Carson’s continued service. After this grant, Mr. Carson beneficially owns a total of 200,118 shares of Nuvectis Pharma common stock, including restricted shares.
Nuvectis Pharma (NVCT) reported an insider purchase by Chairman & CEO Ron Bentsur. On 11/05/2025, he bought 5,000 shares of common stock at $5.72 per share (transaction code P). Following the trade, his directly held beneficial ownership totals 3,525,924 shares.
The total includes 676,759 shares of restricted stock, as noted in the footnote. Bentsur is listed as Director, Chairman & CEO, and a 10% Owner, with the reported holdings shown as Direct (D).
Nuvectis Pharma (NVCT) director reported an open-market purchase of 13,000 shares on November 5, 2025 at a weighted average price of $5.79. After the transaction, the director beneficially owned 78,150 shares directly and 415 shares indirectly as custodian for a son. The filing notes the purchase was executed through multiple same-day trades within a price range of $5.77 to $5.81, consolidated as a single line item.
Nuvectis Pharma (NVCT): Director Matthew Kaplan purchased 11,000 shares of common stock on 11/05/2025 in an open‑market transaction coded “P” at a weighted average price of $5.84. Following this trade, he beneficially owns 124,760 shares, held directly.
The filing notes the price was a weighted average across multiple same‑day trades within a $5.81–$5.88 range, and detailed breakdowns are available upon request.
Nuvectis Pharma (NVCT) reported a Form 4 for director Juan Sanchez showing the acquisition of 30,000 shares of restricted common stock on 09/22/2025 at a stated price of $0. The award vests in equal annual installments over three years beginning on the first anniversary of the grant date, contingent on his continued service on the Board.
After the reported transaction, Dr. Sanchez beneficially owned 65,150 shares directly and 415 shares indirectly as custodian for his son.
Nuvectis Pharma (NVCT) reported insider purchases by director Charles Mosseri‑Marlio. He indirectly acquired common stock across three open‑market transactions: 46,900 shares at $6.06 on October 23, 35,034 shares at $6.15 on October 24, and 72,836 shares at $6.28 on October 27.
Following these trades, he beneficially owned 3,136,576 shares, held indirectly through Emerald Hill Ventures SARL SPF, of which he is the beneficial owner.